Expression and function of B7-1 (CD80) and B7-2 (CD86) on human epidermal Langerhans cells

In addition to T cell receptor triggering, activation of T cells requires co-stimulatory signals that have been shown to be mainly initiated through CD28. We analyzed the expression and function of the two ligands for CD28, B7-1 (CD80) and B7-2 (CD86), on human Langerhans cells (LC), the antigen-presenting cells from epidermis. Human LC freshly isolated from epidermis (fLC) expressed significant level of B7-2, which was increased upon a short culture in vitro. In contrast, B7-1 was undetectable on fLC but appeared at the cell surface after a 3-day culture in vitro. Pre-incubation of 18-h cultured LC with anti-B7-2 monoclonal antibodies (mAb) was sufficient to abrogate the binding of CTLA4-Ig fusion protein, while a combination of both mAb against B7-1 and B7-2 was necessary to obtain a complete inhibition of CTLA4-Ig binding on 3-day cultured LC, showing the absence of a third CTLA4 ligand. The function of B7-1 and B7-2 on human LC has been analyzed by adding mAb at the beginning of mixed epidermal cell lymphocyte reactions. Anti-B7-2 mAb and CTLA4-Ig, but not anti-B7-1 mAb, strongly inhibited allogeneic, as well as recall antigen-induced T cell proliferation supported by fLC or 3-day cultured LC. Collectively, these results demonstrate that B7-2 is the major ligand for CD28/CTLA4 at the LC surface and that it plays a crucial role in human LC co-stimulatory function with little, if any, dependence on B7-1 expression.     

Cryptococcus neoformans differently regulates B7-1 (CD80) and B7-2 (CD86) expression on human monocytes

To induce a specific response in primary resting T cells, two signals must be provided by antigen-presenting cells (APC). The first antigen-specific signal is mediated by formation of the T cell receptor major histocompatibility complex molecule ternary complexes. The second signal is delivered by interaction of either B7-1 or B7-2 expressed by APC with CD28 or CTLA-4 on T cells. In this study, we examined the modulation of B7-1 and B7-2 molecules on human monocytes exposed to encapsulated or acapsular Cryptococcus neoformans or Candida albicans. In our experimental system, C. albicans or acapsular C. neoformans are able to induce B7-1 expression while the encapsulated yeast is a poor stimulator. A modest increase of B7-2 expression was also observed after monocyte treatment with acapsular C. neoformans or C. albicans, while the encapsulated yeast was ineffective in inducing B7-2 molecules. Kinetic analysis showed the maximum expression of B7-1 after 24 to 48 h. Addition of the opsonic IgG1 mAb 2H1 to monocytes and C. neoformans significantly increased B7-1, but not B7-2, expression. The contribution of B7-1 and B7-2 co-stimulatory (CS) molecules to cryptococcal-specific T cell activation was analyzed and a substantial inhibition of T cell proliferation was observed. In this study we provide the first demonstration of fungal interference in the regulation of CS molecules. Our results suggest a potential mechanism for poor inflammatory responses observed in C. neoformans infections.     

Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes

There is evidence that interleukin ?10(IL-10) interferes with the costimulatory properties of antigen-presenting cells and, thereby, inhibits their ability to induce T cell activation. To determine whether this effect might involve modulation of the expression of accessory molecules, we analyzed by flow cytometry the influence of human IL-10 on the basal expression of intercellular adhesion molecule 1 (ICAM-1) as well as on the interferon γ(IFN-γ)-induced up-regulation of ICAM-1 and B7 at the surface of human monocytes. IL-10 inhibited both the basal expression and the IFN-γ-induced ICAM-1 up-regulation. IL-10 also reduced B7 up-regulation on IFN-γ-stimulated monocytes. The inhibitory effect of IL-10 both on ICAM-1 and B7 expression was shown to be dose dependent. We conclude that the ability of IL-10 to decrease both ICAM-1 and B7 expression on monocytes might contribute to its immunosuppressive properties.     

Both CD28 ligands CD80 (B7-1) and CD86 (B7-2) activate phosphatidylinositol 3-kinase, and wortmannin reveals heterogeneity in the regulation of T cell IL-2 secretion

In this report, the co-stimulatory signals provided by CD80(B7-1) or CD86 (B7-2) were compared to CD28 ligation by mAb.We demonstrate that while both anti-CD3 and anti-CD28 antibodiesinduced activation of phospholnositide (PI) 3-kinase, the kineticsof activation differed. Anti-CD28 produced a sustained activationof PI 3-kinase while anti-CD3 induced activation was transient.Both B7-1 and B7-2 could induce prolonged activation of PI 3-kinase.The co-stimulatory effects of B7-1 and B7-2 were dependent onCD28 cross-linking, based on complete inhibition of PI 3-kinaseactivation by CD28 antibody Fab fragments. While Jurkat T cellsco-stimulated with anti-CD3 and B7-1 or B7-2 secreted high levelsof IL-2, there were distinct effects of anti-CD28 mAb and B7-1or B7-2 on IL-2 secretion in conjunction with protein kinaseC activation. To assess functional effects of CD28 ligation,pharmacologic inhibitors of PI 3-kinase were evaluated. In Jurkatcells, efficient inhibition of PI 3-kinase activation afterB7-2 stimulation was achieved using wortmannin; however, weobserved a surprising increase in IL-2 secretion after B7 oranti-CD28 stimulation. The effect of wortmannin was concentrationdependent. Moreover, the effect was specific for receptor-mediatedactivation as wortmannin did not enhance phorbol ester pluslonomycin-induced IL-2 secretion. Another inhibitor of PI 3-kinase,LY294002, also resulted in augmentation of anti-CD28-inducedIL-2 secretion by Jurkat cells. The effects of wortmannin onIL-2 secretion were also examined in primary T cells. In markedcontrast, wortmannin resulted in a potent inhibition of anti-CD3plus B7-1 or anti-CD28-induced IL-2 secretion while phorbolester plus lonomycin-induced IL-2 secretion was wortmannin resistant.Together these observations demonstrate that signal transductionby both B7-1 and B7-2 involves PI 3-kinase, and that PI 3-kinaseor other wortmannin-sensitive targets are important for IL-2secretion. Finally, treatment of Jurkat cells with PI 3-kinaseinhibitors alone was sufficient to induce low levels of IL-2secretion. This is consistent with the notion that a wortmannin-sensitivetarget such as PI 3-kinase may down-regulate IL-2 secretionin Jurkat cells.     

Peripheral blood antigen-presenting cells from African-Americans exhibit increased CD80 and CD86 expression.

Despite the increased incidence and severity of many autoimmune diseases and transplant rejection in African-Americans (AA) compared with Caucasians (CS), very few studies have addressed issues of racial variation during antigen presentation. This investigation was performed as a preliminary exploration of differences in peripheral blood cell costimulatory functions between healthy AA (n = 20) and CS (n = 20) subjects. The expression of surface costimulatory molecules on peripheral blood cells, mononuclear cells enriched by Ficoll density centrifugation, and plastic adherent antigen-presenting cells (APC) was determined by flow cytometry using fluorescent-labelled MoAbs. The expression of both B7 costimulatory molecules was significantly higher on the cells from AA subjects compared with cells from CS subjects (CD80, P < 0.05; CD86, P < 0.05). Also, following 18 h of culture with rhIL-1beta, there was a significant increase in the percentage of APC from AA expressing high levels of the costimulatory molecule CD80 (P < 0.05). Costimulatory function during mitogen and antigen presentation was determined by 3H-thymidine incorporation during T cell proliferation. Purified T cells from AA subjects demonstrated significantly increased proliferation to phytohaemagglutinin (PHA). The differences reported here suggest that racial variations in peripheral blood APC characteristics may exist. Given the importance of costimulation in maintaining long-term immune responses, these data suggest a further direction for the investigation of racial disparity in autoimmune disease pathology and transplant rejection rates.     

可溶性小鼠BTLA对树突状细胞表面B7-1和B7-2表达的影响

目的研究可溶性小鼠B/T淋巴细胞弱化因子（murine B and T lymphocyte attenuator ，mBTLA）-人IgG1 Fc融合蛋白（mBTLA-hIg）对树突状细胞表面共刺激分子表达的影响。方法克隆mBT／A基因，构建mBTLA胞外功能区和人IgG1Fc融合基因的真核表达载体（pmBTLA-hIg），并采用脂质体转染法，将pmBTLA-hIg质粒转染小鼠树突状细胞系（DC2．4）。采用RT-PCR、ELISA和Westem blot分别检测pmBTLA-hIg质粒转染DC中mBTLA基因mBNA的表达及细胞培养上清中mBTLA-hIg融合蛋白的表达；采用流式细胞术检测pmBTLA-hIg质粒转染对DC2．4表面共刺激分子B7-1（CD80）和B7-2（CD86）表达的影响。结果成功克隆了小鼠BT／A基因，并构建了真核表达载体；mBTLA-hIg融合基因转染的DC高表达mBTLA-hIg融合蛋白，并可结合到DC表面。表达可溶性mBTLA-hIg融合蛋白的DC2．4表面B7．1的表达上调，B7-2的表达下调，而且这种改变可被兔抗GST-mBTLA血清阻断。结论可溶性mBTLA-hIg融合蛋白对DC细胞表面研分子的表达具有调节作用，可能是BTLA反向信号作用于DC的结果。     

Reciprocal expression of co-stimulatory molecules,B7-1 and B7-2, on murine T cells following activation

The co-stimulatory B7 molecules (B7-1 and B7-2) are expressed on professional antigen-presenting cells in mice. In this study, we demonstrate that B7-1 (CD80) and B7-2 (CD86) are also expressed on murine T cells in the absence of major histocompatibility complex class II molecules. The temporal expression of these two molecules on T cells varies with the state of activation where resting T cells express B7-2 but show little or no expression of B7-1. Following activation, B7-2 expression is down-regulated and there is a concomitant increase in the expression of B7-1 on the cell surface which peaks at about 72 h. Thus these two co-stimulatory molecules are reciprocally expressed on the T cell surface. This pattern of expression of B7-1 and B7-2 on T cells suggests that these two molecules may have different roles in the generation and regulation of immune responses.     

慢性乙型肝炎患者外周血树突细胞CD40、CD80表达和免疫活性的体外研究

目的 :探讨慢性乙型肝炎患者DC表面协同刺激分子CD4 0和CD80表达与其抗原呈递功能的关系 ,为进一步研究慢性乙型肝炎的发病机制及治疗提供新的思路。方法 :分离培养慢性乙型肝炎患者和健康人外周血DC ,流式细胞仪测定DC表面CD4 0和CD80的表达 ,混合淋巴细胞反应测定两组DC的功能。结果 :慢性乙型肝炎患者DC表面CD4 0和CD80的表达较健康人低 ,刺激同种异种T细胞增殖反应也较健康人低。结论 :乙肝病毒感染可通过抑制患者DC表面CD4 0、CD80等协同刺激分子的表达 ,从而使其抗原呈递功能降低     

共刺激分子4-1BBL和B7-1对人T淋巴细胞的协同激发作用

目的 :探讨 4 1BBL和B7 1这 2种共刺激分子在人外周血T淋巴细胞活化、增殖中的作用和机制。方法 :采用免疫磁珠阴性选择方法分离纯化人外周血T淋巴细胞 ;单向混合淋巴细胞反应 (MLR)分析共刺激分子对T细胞的激发作用 ;3H TdR掺入法测定细胞增殖 ;免疫荧光标记和流式细胞仪表型分析 ;ELISA检测细胞因子。结果 :经免疫磁珠阴性选择分离获外周血单个核细胞中的T细胞纯度 >90 %;人多发性骨髓瘤细胞株 (XG细胞 )转染 4 1BBL和B7 1cDNA后 ,细胞膜表面能稳定高表达这 2个分子 ,4 1BBL和B7 1转基因细胞也均能使同种异体T细胞发生活化、增殖、存活时间延长和介导细胞因子IL 2的分泌 ,且 2种共刺激分子具有一定的协同效应。结论 :4 1BBL和B7 1分子具有赋予XG细胞对T细胞的体外激发、促增殖和分泌IL 2的作用 ,4 1BBL和B7 1分子能产生协同效应。     

B7-H1阻断对未成熟树突状细胞免疫功能的影响

目的：探讨B7-H1阻断对未成熟树突状细胞(DCs)的免疫刺激活性的影响。 方法： 以细胞因子GM-CSF和IL-4体外诱导人单核细胞来源的树突状细胞，流式细胞仪检测在诱导过程中B7-H1的表达，并以B7-H1单抗阻断处理，分别以流式细胞仪、MTT法、ELISA、ELISPOT法检测B7-H1阻断对DCs的成熟和内吞能力、刺激淋巴细胞增殖、IL-12的分泌、诱导淋巴细胞分化的影响。 结果： DCs在诱导过程中B7-H1表达逐渐增强，第7 d时的阳性表达率为54.12％，以TNF-α诱导成熟后阳性表达率为83.64％；B7-H1阻断对DCs成熟和内吞能力无影响，但可使未成熟DCs刺激淋巴细胞增殖的能力和IL-12的分泌明显增强，并诱导淋巴细胞向分泌IFN-γ的Th1/Tc1的分化。 结论： B7-H1阻断可增强未成熟DCs的免疫刺激活性，利用B7-H1阻断的DCs瘤苗激发抗肿瘤免疫的方案值得进一步探讨。     

Comparative analysis of B7-1 and B7-2 expression in Langerhans cells: differential regulation by T helper type 1 and T helper type 2 cytokines

Epidermal Langerhans cells (LC) are Ia-bearing potent antigen-presenting cells (APC) of dendritic cell lineage that play a crucial role in primary and secondary T cell-dependent immune responses. LC express several costimulatory molecules such as B7, which has been implicated as one of the important determinants of professional APC. Recently, B7 antigens have been shown to include three distinct molecules termed B7-1, B7-2, and B7-3, and the expression of B7-1 and B7-2 in LC has been already confirmed. However, little is known of the regulation of B7-1 and B7-2 expression in LC. We demonstrated that LC do not express B7-1 and B7-2 in situ; however, the expression of both molecules is rapidly induced during the first 3 days of culture, and high levels of expression are maintained at least until day 6. We show that the expression of B7-2 in LC is much higher than that of B7-1 in each experiment, and that B7-1 and B7-2 expression is reproducibly augmented by interleukin (IL)-4 in a dose-dependent manner; however, IL-2 affected expression very little. Finally, B7-1 expression is significantly and dose-dependently down-regulated by interferon (IFN)-γ or IL-10, and B7-2 expression is consistently inhibited by IL-10, but not by IFN-γ. The effects of these cytokines are active only in the induction phase (during first 3 days of culture) of B7 expression: the modulatory effects of cytokines are hardly detected in the plateau phase (days 4 to 6 of culture) of B7 expression in LC. These findings suggest that B7-1 and B7-2 expression are indeed selectively and differentially regulated by these T cell-derived cytokines, and that the cytokines may modulate the synthesis of B7 molecules rather than the degradation of already-expressed B7 molecules.     

Interleukin-10 prevents the generation of dendritic cells from human peripheral blood mononuclear cells cultured with interleukin-4 and granulocyte/ macrophage-colony-stimulating factor

We evaluated the effects of interleukin (IL)-10 on the differentiation of dendritic cells (DC) obtained by culturing plastic-adherent peripheral blood mononuclear cells for 7 days in presence of granulocyte/macrophage-colony-stimulating factor (GM-CSF)+IL-4. The addition of IL-10 at the initiation of culture resulted in the generation of macrophage-like cells with expressing high levels of CD14 and decreased levels of CD1a and CD1c. Furthermore, cells generated in presence of IL-10 secreted lower levels of IL-12, but higher levels of IL-8 compared with DC generated in absence of IL-10, both spontaneously and after CD40 engagement. Finally, cells generated in presence of IL-10 were less efficient than DC in stimulating the production of IL-2, interferon-γ, and IL-4 by allogeneic T cells. We conclude that IL-10 prevents the generation of DC induced by GM-CSF+IL-4 and favors the development of macrophages with a lower T cell stimulatory potential, but secreting higher levels of IL-8 than DC.     

Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition

Clinical data and animal models afford evidence for anti-leukemia immunity in humans, but the interactions critical for blast cell recognition are unresolved. Expression of B7 molecules by antigen-presenting cells (APC) provides co-stimulatory signals to T lymphocytes via CD28 and CTLA-4 which prevent the induction of alloantigen-specific tolerance. Conversely, expression of CD40 ligand by stimulated T cells activates APC via CD40. In human hematological B cell malignancies (follicular lymphoma and chronic lymphocytic leukemia), the defect in alloantigen presentation of tumoral cells can be repaired by up-regulation of B7 and other co-stimulatory molecules via CD40. We studied the role of B7 molecules in alloimmune recognition and the various ways to improve the antitumoral response on peripheral blood leukemic cells from 20 patients with a diagnosis of primary acute myeloid leukemia (AML). We focused on myelo/monocytic M4/M5 French-American-British classification subtypes which are considered as the neoplastic counterpart of normal monocytes, a prototypic APC. In one-way mixed lymphocyte reaction of CD4+ T cells against leukemic cells, differences in B7-1, B7-2 or CD40 expression by AML cells did not induce specific cytokine secretion; interleukin (IL)-2 and interferon (IFN)-γ were detected but not IL-4, corresponding to a Th1 pattern. Blockade experiments showed that proliferation and IFN-γ secretion only partially depended on B7 molecules, which in contrast had a pivotal role in IL-2 synthesis. In contrast with murine models which suggest a pivotal role for CD80/B7-1 in the immune response against AML, our data support a greater role for CD86/B7-2, in line with the baseline expression of CD86/B7-2 and lack of CD80/B7-1 on most M4/M5 AML cells. AML cell stimulation via CD40: (1) significantly improved IL-2 secretion but not proliferation of responding T lymphocytes, (2) increased CD54/ICAM-1 expression in three quarters of cases, (3) failed in most cases to induce CD40-specific CD80/B7-1 up-regulation and (4) had a weak effect on CD86/B7-2 expression. These data contrast with the very efficient up-regulation of both B7 co-stimulatory molecule expression and tumoral cell alloimmune recognition following CD40 stimulation in B cell malignancy models. The role of the defective B7 molecule up-regulation by the CD40 pathway in inefficient tumor immunogenicity of primary AML cells has to be further investigated, in particular using transfection experiments of CD80/B7-1-deficient AML cell lines. From our in vitro data we conclude that B7 molecules play an important role in the alloimmune surveillance of AML as suggested by the high B7 molecule dependency of IL-2 secretion. Nonetheless, the contribution of B7 molecules to alloimmune T cell proliferation against primary AML cells in human and the way to improve it – regulation via CD40 in particular – differ from B cell malignancies and murine models, suggesting the requirement for specific strategies in the development of antitumor immunity.     

Interferon-γ and interleukin-10 inhibit antigen presentation by Langerhans cells for T helper type 1 cells by suppressing their CD80 (B7-1) expression

CD80(B7-1) and CD86(B7-2) co-stimulatory molecules have been reported to activate Th1/Th2 development pathways differentially. It is well known that Langerhans cells (LC), potent antigen-presenting dendritic cells in the epidermis, express several co-stimulatory molecules and that this expression is modulated by several cytokines. Based on the recently reported effect of interferon (IFN)-γ and interleukin (IL)-10 on the expression of CD80 and CD86 by LC, we examined the effects of these cytokines on the expression of CD54 (intercellular adhesion molecule-1) and CD40 in addition to CD80 and CD86 on LC, and correlated the expression of each co-stimulatory molecule with antigen presentation for a Th1 clone by cultured LC (cLC) treated with these cytokines. LC cultured for 72 h significantly up-regulated MHC class II antigen expression and all the co-stimulatory molecules we examined. As previously reported, IL-10 or IFN-γ inhibited the up-regulation of CD80 expression. Granulocyte/macrophage-colony-stimulating factor (GM-CSF) partially restored the suppression of CD80 expression induced by IFN-γ on cultured LC, while it had virtually no effect on the inhibition induced by IL-10. Antigen presentation for the myoglobin-specific syngeneic Th1 clone by cLC, which were pre-incubated with these cytokines, correlated well with their CD80 expression. In addition, among the antibodies for CD80, CD86, CD28 or CD40, the suppression of the Th1 clone stimulation by LC was found to occur only with anti-CD80 and anti-CD28 antibodies. Finally, we studied the effects of IFN-γ and IL-10 on GM-CSF production by epidermal keratinocytes (KC). We could show that only IFN-γ, but not IL-10, suppressed GM-CSF production by KC. These findings suggest that both IFN-γ and IL-10 suppress antigen presentation by LC for Th1 cells by suppressing their CD80 expression. The inhibitory effect of IFN-γ on CD80 expression on LC appears to be partially mediated through the suppression of GM-CSF production by KC.     

Interleukin-7 specifically induces the B7/BB1 antigen on human cord blood and peripheral blood T cells and T cell clones

B7/BB1 is a cell surface molecule and member of the Ig superfamily that is constitutively expressed on dendritic cells.In addition, B7 is expressed on B cells, macrophages, T cells,and T cell clones following activation. Interaction of B7 withits natural ligand CD28 is required for optimal stimulationof T cells, activated via the TCR-CD3 complex, which is thoughtto be due to stabilization of cytokine mRNA. Here we demonstratethat the expression of B7 on T cells can specifically be inducedby IL-7. Induction of B7 expression on T cells and T cell clonesrequires at least 5 – 7 days of culture and representsa late activation event. Results of studies using T cell clones,as well as resting purified B7^– T cells, demonstrate thatB7 is induced on a substantial proportion of T cells after IL-7activation and is not due to an outgrowth of pre-existing B7+T cells. In addition, CD4+ as well as CD8+ T cells could beinduced to express B7. Stimulation of purified cord blood Tcells with cross-linked anti-CD3 mAb resulted in a relativelyfast (48 h) induction of B7, which could not be inhibited bya neutralizing anti-IL-7 mAb, whereas no endogenous IL-7 productionby activated T cells and T cell clones could be detected. Together,these results indicate that the B7 molecule can be induced onT cells by IL-7, but also by an IL-7 independent pathway involvingtriggering of the TCR-CD3 complex.     

Costimulatory molecules in Wegener's granulomatosis (WG): lack of expression of CD28 and preferential up-regulation of its ligands B7-1 (CD80) and B7-2 (CD86) on T cells

T cells are most likely to play an important role in the pathogenesis of WG, and recently a predominant Th1 pattern of immune response has been demonstrated in granulomatous inflammation. Since the expression of costimulatory molecules has a significant impact on the cytokine profile and proliferation response of T cells, the goal of this study was to characterize the expression of costimulatory molecules (CD28, CTLA-4 (CD152), B7-1 (CD80), B7-2 (CD86)) on T cells, monocytes and B cells in WG, and to correlate the findings with clinical parameters such as disease activity, extent and therapy. WG patients (n = 24) and healthy controls (HC; n = 17) were examined for the expression of costimulatory molecules by fluorescence-activated cell sorter analysis, both in whole peripheral blood and after in vitro activation of T cells and antigen-presenting cells. Results were correlated with clinical data. The expression of CD28 on CD4⁺ and CD8⁺ cells was significantly lower in WG than in HC (CD28⁺ 81.4% in WG versus 97.9% of CD4⁺ cells (P < 0.0001); CD28⁺ 44.6% in WG versus 68.5% of CD8⁺ cells (P < 0.00001)), both in peripheral blood and after in vitro activation. A lower percentage of monocytes was B7-2⁺ in WG than in HC in peripheral blood, whereas no significant differences in the expression of B7-1 and B7-2 were observed after in vitro stimulation of monocytes and B cells. After in vitro activation a significantly higher percentage of B7-1⁺ and B7-2⁺ T cells was seen in WG. There was no significant difference in the CTLA-4 expression pattern between WG and HC. The percentage of CD28⁺ lymphocytes correlated negatively with the Disease Extent Index cumulated over the course of disease (r = ?0.46, P = 0.03), indicating a more severe manifestation in patients with lower CD28 expression. Correlations with other clinical parameters such as activity or therapy were not seen. WG patients show a lack of CD28 expression on T cells and an unusual up-regulation of its ligands B7-1 and B7-2 on T cells after in vitro activation as well as a lower expression of B7-2 on freshly isolated monocytes compared with HC. These features might promote the Th1 cytokine pattern and thereby contribute to persistently high levels of immune activation in WG.     

人B7-2(CD86) IgV+C段高效原核表达及活性测定

目的克隆、表达B7-2(IgV+C)并进行体外功能测定.方法用聚合酶链反应(PCR)技术从B7-2 cDNA中克隆B7-2(IgV+C),在此基础上构建表达B7-2(IgV+C)的原核表达载体pGEX-4T-3/hB7-2(IgV+C);SDS-PAGE检测蛋白表达,蛋白经变性、复性后在体外协同抗CD3单抗刺激人T细胞,3H-TdR掺入法检测T细胞的活化程度.结果在原核表达载体中成功地克隆了B7-2(IgV+C),SDS-PAGE表明在相对分子质量(Mr)55×103处有hB7-2(IgV+C)/GST融合蛋白的高效表达,其表达量占菌体总蛋白的33%.体外实验证明,此融合蛋白可协同抗CD3单抗刺激人T细胞活化.结论重组蛋白B7-2(IgV+C)在第一信号存在下可活化T细胞,即具有共刺激活性.